ストックスクリーナーアプリを入手
7.78
1.77%
-0.14
アフターアワーズ：
7.80
0.02
+0.26%
前日終値:
$7.92
開ける：
$8.02
24時間の取引高:
61,026
Relative Volume:
0.67
時価総額：
$754.61M
収益：
$116.59M
当期純損益:
$9.88M
株価収益率:
345.78
EPS:
0.0225
ネットキャッシュフロー:
$-2.40M
1週間 パフォーマンス:
+1.43%
1か月 パフォーマンス:
+9.27%
6か月 パフォーマンス:
+5.28%
1年 パフォーマンス:
-11.69%
1日の値動き範囲:
$7.68
$8.05
1週間の範囲:
$7.30
$8.05
52週間の値動き範囲:
$6.57
$11.78
Gyre Therapeutics Inc Stock (GYRE) Company Profile
名前
Gyre Therapeutics Inc
セクター
電話
(858) 567-7770
住所
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.78 | 768.19M | 116.59M | 9.88M | -2.40M | 0.0225 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | 開始されました | Jefferies | Buy |
| 2025-08-26 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-11 | 開始されました | Noble Capital Markets | Outperform |
| 2021-04-29 | 再開されました | Stephens | Overweight |
| 2021-02-10 | 開始されました | Piper Sandler | Overweight |
| 2020-05-21 | 開始されました | Raymond James | Outperform |
| 2019-01-04 | 開始されました | Oppenheimer | Outperform |
| 2018-02-12 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-12-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 開始されました | Chardan Capital Markets | Buy |
| 2017-06-06 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-06-30 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
Gyre Therapeutics Inc (GYRE) 最新ニュース
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S. and China-based Fully Integrated Biopharmaceutical Company - marketscreener.com
Gyre Therapeutics Acquires Cullgen in $300M All-Stock Deal to Form Fully Integrated U.S.-China Biopharma Company Focused on Fibrosis and Inflammatory Diseases - Minichart
Gyre Therapeutics Completes $300 Million All-Stock Acquisition of Cullgen - Moomoo
Gyre Therapeutics closes $300M Cullgen acquisition - Investing.com
Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition - TipRanks
Gyre Therapeutics (GYRE) closes $300M Cullgen deal, adds degrader pipeline - Stock Titan
A $300M biotech merger gives Gyre a China drug business and new CEO - Stock Titan
Gyre Therapeutics Completes Acquisition Of Cullgen To Create U.S.- And China-Based Fully Integrated Biopharmaceutical Company - TradingView
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company - Benzinga
GYRE Stock Price, Quote & Chart | GYRE THERAPEUTICS INC (NASDAQ:GYRE) - ChartMill
Gyre Therapeutics (GYRE) Expected to Announce Earnings on Thursday - MarketBeat
New Strong Sell Stocks for Oct. 17th - MSN
Gyre Therapeutics, Inc. (GYRE) Q4 earnings miss estimates - MSN
US High Growth Tech Stocks To Watch - Sahm
Gyre Therapeutics | DEF 14A: Definitive information statements - Moomoo
Gyre Therapeutics | DEFA14A: Others - Moomoo
[ARS] GYRE THERAPEUTICS, INC. SEC Filing - Stock Titan
Cullgen all-stock merger and share conversion plans at Gyre (NASDAQ: GYRE) - Stock Titan
GYRE (Gyre Therapeutics Inc.) notches 10.2 percent year over year revenue growth, shares climb despite modest EPS miss.Seasonality - UBND thành phố Hải Phòng
GYRE (Gyre Therapeutics) Q4 2025 revenue rises 10.2 percent YoY, misses EPS estimates as shares fall 2.28 percent.Margin Improvement - Xã Vĩnh Công
Gyre Therapeutics (GYRE) Stock Cancelled Order (Bullish Momentum) 2026-04-18Institutional Flow - Cổng thông tin điện tử Tỉnh Sơn La
Form 8-KCurrent report - ADVFN
Form 424B3Prospectus [Rule 424(b)(3)] - ADVFN
Form S-3Registration statement under Securities Act of 1933 - ADVFN
Form SC 13D/AGeneral statement of acquisition of beneficial ownership: [Amend] - ADVFN
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - ADVFN
[8-K/A] GYRE THERAPEUTICS, INC. Amends Material Event Report - Stock Titan
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring the 136% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Gyre Therapeutics (NASDAQ: GYRE) proxy: $300M Cullgen merger and Series B conversion - Stock Titan
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2%Should You Buy? - MarketBeat
Gyre Therapeutics (GYRE) Q2 2024 earnings summary - Quartr
Gyre Therapeutics (GYRE) Proxy Filing Summary - Quartr
Gyre Therapeutics (GYRE) Q3 2025 earnings summary - Quartr
Growth Recap: Is Gyre Therapeutics Incs ROE strong enoughDip Buying & High Conviction Trade Alerts - baoquankhu1.vn
Is Gyre Therapeutics (GYRE) Stock Ready to Rally | Price at $7.55, Up 2.23%Fast Rising Picks - Newser
Is Gyre Therapeutics (GYRE) Stock in consolidation phase | Price at $7.08, Down 0.14%Crowd Entry Signals - Newser
GYRE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Dow Update: Does Gyre Therapeutics Inc offer margin of safetyMarket Performance Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
Rate Hike: Is Gyre Therapeutics Inc stock showing strong momentumWeekly Gains Report & Safe Capital Growth Stock Tips - baoquankhu1.vn
GYRE PE Ratio & Valuation, Is GYRE Overvalued - Intellectia AI
Gyre Therapeutics (GYRE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring A 162% Potential Upside - DirectorsTalk Interviews
Growth Value: How do insiders feel about Gyre Therapeutics IncPortfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Portfolio Shifts: How do insiders feel about Gyre Therapeutics Inc2026 Major Catalysts & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
Rally Mode: Is Gyre Therapeutics Inc a turnaround story2026 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Will Gyre Therapeutics Inc stock hit new highs in YEAR2026 Spike Watch & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Gyre Therapeutics Files NDA in China for F351 - The Globe and Mail
Gyre Therapeutics (GYRE) to Release Earnings on Tuesday - MarketBeat
Gyre Therapeutics Inc (GYRE) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):